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tyrosine kinase inhibitors 1750

tyrosine kinase receptor 407

uPA 139

upper aerodigestive tract cancer 1852

urinary biomarker 1772

urinary bladder cancer 1180

urinary bladder neoplasms 444

uterine serous cancer 1750

UV radiation 1810

uveal melanoma 1373

vaccine 1824

vaginal brachytherapy 674

validation 470

VEGF-signalling inhibitors 1590

vemurafenib 640, 1625

vitamin D intake 976

vitamin D supplements 976

vitamin supplement 2220

volatile organic compound 790

von Willebrand factor 1742

Withacnistin 894

withdrawal response 2046

Wnt/*β*-catenin signalling 132

XELOX 241

xenograft 365

zoledronic acid 1139
